Tissue-engineered decellularized extracellular matrix (ECM) scaffolds hold great potential to
address the donor shortage as well as immunologic rejection attributed to cells in …

Upregulation of sialyltransferases—the enzymes responsible for the addition of sialic acid to
growing glycoconjugate chains—and the resultant hypersialylation of up to 40–60% of …

Protein aggregation in biotherapeutics has been identified to increase immunogenicity,
leading to immune-mediated adverse effects, such as severe allergic responses including …

Over recent decades, therapeutic proteins have had widespread success in treating a
myriad of diseases. Glycosylation, a near universal feature of this class of drugs, is a critical …

The circulatory half-life of recombinant therapeutic proteins is an important pharmacokinetic
attribute because it determines the dosing frequency of these drugs, translating directly to …

Chondroitin sulfate (CS) is a well-known glycosaminoglycan present in a large variety of
animal tissues, with an outstanding structural heterogeneity mainly related to molecular …

Prostate Cancer (PCa) is the most commonly diagnosed malignancy and second leading
cause of cancer-related mortality in men. With the use of next generation sequencing and …

Human immunoglobulin G (IgG), especially autoantibodies, has major implications for the
diagnosis and management of a wide range of autoimmune diseases. However, some …

Nearly all extracellular proteins undergo post-translational modification with sugar chains
during their transit through the endoplasmic reticulum and the Golgi apparatus. These …

The receptor binding domain (RBD) of the SARS-CoV-2 spike protein plays a key role in the
virus-host cell interaction, and viral infection. The RBD is a major target for neutralizing …